R
Raffael Nachbagauer
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 76
Citations - 3841
Raffael Nachbagauer is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Hemagglutinin (influenza) & Virus. The author has an hindex of 28, co-authored 68 publications receiving 2621 citations. Previous affiliations of Raffael Nachbagauer include Crips & University of Vienna.
Papers
More filters
Journal ArticleDOI
Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity
Susana V. Bardina,Paul Bunduc,Shashank Tripathi,James Duehr,Justin J. Frere,Julia A. Brown,Raffael Nachbagauer,Gregory A. Foster,David E. Krysztof,Domenico Tortorella,Susan L. Stramer,Adolfo García-Sastre,Florian Krammer,Jean K. Lim +13 more
TL;DR: Using convalescent plasma from DENV- and WNV-infected individuals, substantial enhancement of ZIKV infection in vitro was found that was mediated through immunoglobulin G engagement of Fcγ receptors, highlighting the need to exert great caution when designing flavivirus vaccines.
Journal ArticleDOI
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Dorottya Laczkó,Michael J. Hogan,Sushila A. Toulmin,Philip Hicks,Katlyn Lederer,Brian T. Gaudette,Diana Castaño,Diana Castaño,Fatima Amanat,Hiromi Muramatsu,Thomas H. Oguin,Amrita Ojha,Lizhou Zhang,Zekun Mu,Robert Parks,Tomaz B. Manzoni,Brianne Roper,Shirin Strohmeier,István Tombácz,Leslee Arwood,Raffael Nachbagauer,Katalin Karikó,Jack Greenhouse,Laurent Pessaint,Maciel Porto,Tammy Putman-Taylor,Amanda Strasbaugh,Tracey Ann Campbell,Paulo J.C. Lin,Ying K. Tam,Gregory D. Sempowski,Michael Farzan,Hyeryun Choe,Kevin O. Saunders,Barton F. Haynes,Hanne Leth Andersen,Laurence C. Eisenlohr,Laurence C. Eisenlohr,Drew Weissman,Florian Krammer,Paul Bates,David Allman,Michela Locci,Norbert Pardi +43 more
TL;DR: It is suggested that the nucleoside-modified mRNA-LNP vaccine platform can induce robust immune responses and is a promising candidate to combat COVID-19.
Journal ArticleDOI
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
Raffael Nachbagauer,Jodi Feser,Abdollah Naficy,David I. Bernstein,David I. Bernstein,Jeffrey T. Guptill,Emmanuel B. Walter,Emmanuel B. Walter,Franceso Berlanda-Scorza,Daniel Stadlbauer,Patrick C. Wilson,Teresa Aydillo,Mohammad Amin Behzadi,Disha Bhavsar,Carly M. Bliss,Christina Capuano,Juan Manuel Carreño,Veronika Chromikova,Carine Claeys,Lynda Coughlan,Alec W. Freyn,Chris Gast,Andres Javier,Kaijun Jiang,Chiara Mariottini,Meagan McMahon,Monica M. McNeal,Monica M. McNeal,Alicia Solórzano,Alicia Solórzano,Shirin Strohmeier,Shirin Strohmeier,Weina Sun,Marie Van der Wielen,Bruce L Innis,Adolfo García-Sastre,Peter Palese,Florian Krammer +37 more
TL;DR: The results suggest that chimeric hemagglutinins have the potential to be developed as universal vaccines that protect broadly against influenza viruses.
Journal ArticleDOI
Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice
Teddy John Wohlbold,Raffael Nachbagauer,Raffael Nachbagauer,Haoming Xu,Gene S. Tan,Ariana Hirsh,Karl A. Brokstad,Rebecca Jane Cox,Rebecca Jane Cox,Peter Palese,Florian Krammer +10 more
TL;DR: The demonstrated homologous and heterologous protective capacity of recombinant NA suggests that supplementing vaccine formulations with a standard amount of NA may offer increased protection against influenza virus infection.
Journal ArticleDOI
Universal influenza virus vaccines and therapeutic antibodies
TL;DR: An overview of universal influenza virus vaccines and therapeutic antibodies in preclinical and clinical development and novel therapeutic antibodies against the same conserved targets that could become valuable tools in the fight against influenza virus infection.